Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label trial of flexibly dosed paliperidone ER in schizophrenia after unsuccessful prior oral antipsychotic treatment
2006-004265-34Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in PANSS total score, At least 20% improvement in PANSS total score in prior lack-of-efficacy subgroup and 1 more. Started Jan 2007; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2006-004265-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004265-34.